GlassScriptPhysician profile
Georges C Awah
NPI 1255402418
$5,606.04
in general payments reported to CMS, 2019-2025
27 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $851 · 2021: $1,285 · 2022: $1,082 · 2023: $752 · 2024: $461 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,042.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.50 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $527.72 | 2019-2024 | |
| Glaxosmithkline, LLC. | $510.99 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $460.27 | 2020-2023 | Verquvo |
| Gilead Sciences, INC. | $427.62 | 2019-2025 | Biktarvy |
| Lilly USA, LLC | $415.51 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $379.18 | 2019-2025 | |
| Novo Nordisk INC | $333.27 | 2020-2025 | Wegovy |
| Amgen INC. | $165.65 | 2019-2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $144.43 | 2021-2023 | |
| Exact Sciences Corporation | $115.00 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $91.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $87.52 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $46.51 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $45.76 | 2021 | |
| Mylan Specialty L.P. | $36.84 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $36.42 | 2023 | Opsumit |
| Corcept Therapeutics | $30.49 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $27.22 | 2023 | Amvuttra |
| Boston Scientific Corporation | $27.13 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Dexcom, INC. | $21.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.97 | 2024 | Eliquis |
| Esperion Therapeutics, INC. | $18.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.56 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $17.21 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Awah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.